Baiyunshan Hanfang (Zhuhai Hengqin) Pharmaceutical is a wholly owned subsidiary of Guangzhou Baiyunshan Hanfang Modern Pharmaceutical and has won multiple bids for the Chinese Institute of Drug Control’s procurement project of phospholipid reference standards. The company is capable of large-scale production of high-purity phospholipid raw materials such as yolk phosphatidylethanolamine and phosphatidylcholine. Its 100-gram-scale production technology has broken overseas monopolies, with product purity meeting the CI drug control institute’s tender standards. As a core raw material for nationally mandated phospholipid reference standards, it addresses the industry’s pain point of inconsistent testing standards, leveraging high-purity, cost-effective phospholipid raw materials to promote domestic substitution of pharmaceutical excipients and drive the high-quality upgrading of China’s pharmaceutical industry.
